Inovio Pharmaceuticals, Inc. (INO) Stock: Seeing Declines In Today’s Session

0

Inovio Pharmaceuticals, Inc. (INO) is making a move down in the market in today’s trading session. The stock, focused in the biotechnology space, is presently trading at $2.31 after heading down -5.33% so far in today’s session. In terms of biotechnology companies, there are a number of aspects that have the potential to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines surrounding INO:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-13-19 10:18AM Edited Transcript of INO earnings conference call or presentation 12-Nov-19 9:30pm GMT
10:03AM Inovio’s (INO) Q3 Loss In Line, Sales Lag, VGX-3100 in Focus
Nov-12-19 06:05PM Inovio Pharmaceuticals (INO) Reports Q3 Loss, Misses Revenue Estimates
04:05PM Inovio Pharmaceuticals Reports 2019 Third Quarter Financial Results
08:05AM Merck’s Ebola Vaccine Gets Conditional Approval in Europe

Nonetheless, when making a decision to invest, investors should focus on far more than news, especially in the highly speculative biotechnology industry. Here’s what’s going on with Inovio Pharmaceuticals, Inc..

The Performance That INO Investors Have Experienced

While a move toward the top in a single session, like what we’re seeing from Inovio Pharmaceuticals, Inc. might lead to fear in some investors, a single session move alone should not be the basis of a decision to, or not to, buy a company’s stock. It is always important to look into trends experienced by the stock for a period longer than a single session. As it relates to INO, below are the movements that investors have seen:

  • Weekly – Throughout the last seven days, INO has generated a change in price in the amount of -7.97%.
  • Past 30 Days – The monthly ROI from Inovio Pharmaceuticals, Inc. comes to 3.13%.
  • Past 3 Months – In the past three months, the stock has generated a ROI that comes to 5.48%
  • Past 6 Months – In the past 6 months, we have seen a change that works out to -32.46% from the stock.
  • This Year So Far – Since the open of this year INO has resulted in a return of -42.25%.
  • Annually – Lastly, over the past full year, we have seen movement in the amount of -53.05% out of INO. Over this period, the stock has sold at a high price of -57.77% and a low price of 20.63%.

Crucial Ratios

Looking at a few key ratios having to do with a company can give prospective investors a look of how dangerous and/or potentially profitable a stock pick might be. Here are a few of the most important ratios to look at when digging into INO.

Short Ratio – The short ratio is a tool that’s used to measure the level of short interest. The higher this ratio, the more investors believe that the price of the stock is headed for declines. Across the sector, biotechnology stocks can carry a higher short ratio. However, we also see quite a few short squeezes in the sector. Nonetheless, with regard to Inovio Pharmaceuticals, Inc., the stock’s short ratio is 19.09.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure whether or not a company can cover its debts when they mature based on current assets or quick assets. Because many biotech companies are heavily reliant on the continuation of investor support, the current and quick ratios can be damning. Nonetheless, several better companies in the biotechnology space do have good quick and current ratios. In terms of INO, the quick and current ratios come to 4.60 and 4.60 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this particular case, that ratio is 0.55.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a biotech stock, this is a very important ratio to consider. In this case, the cash to share value comes to 1.05.

How Analysts Feel About Inovio Pharmaceuticals, Inc.

Although it’s never a good idea to unknowingly follow the opinions of analysts, it is a smart idea to use their analysis in order to validate your own before making investment decisions in the biotech space. Here are the recent moves that we’ve seen from analysts as it relates to INO.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-15-18 Reiterated Maxim Group Buy $12 → $8
Oct-18-17 Initiated RBC Capital Mkts Outperform $11
Sep-06-17 Initiated Citigroup Buy $10
Jun-08-17 Upgrade Piper Jaffray Neutral → Overweight
May-24-17 Reiterated Maxim Group Buy $10 → $12

Is Big Money Interested in Inovio Pharmaceuticals, Inc.?

An interesting fact that I have come to understand in my short period in existence has been that smart money tends to follow big money. In other words, investors that are looking to keep the risk down will follow trades made by institutions and insiders. So, what does the big money picture look like as it relates to INO? Here’s the scoop:

  • Institutional Investors – As it stands now, institutions own 42.20% of Inovio Pharmaceuticals, Inc.. On the other hand, it is worth considering that institutional ownership has moved in the amount of 0.78% throughout the last 3 months.
  • Investors On The Inside – As far as insiders go, members of the management team and others close to INO currently hold 2.20% of Inovio Pharmaceuticals, Inc.. Their ownership of the company has moved -51.44% throughout the past 3 months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 101.19M shares of Inovio Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, INO has a float of 94.32M.

I also like to look at the short percentage of the float. Think about it, if a high percentage of the float is sold short, the overall opinion among traders is that the company is headed for a dive. With regard to INO, the short percentage of the float totals up to 12.41%. In general, high short percent of the float is anything over 40%. In my research, I’ve seen that any short ratio over 26% is probably going to be a risky play.

Earnings

What have ween seen from INO in terms of financial results?Here is the data:

  • Analyst Expectations – Currently, analysts are expecting that Inovio Pharmaceuticals, Inc. will create earnings per diluted share that totals up to be -0.85, with -0.26 being reported in the earnings announcement for the current quarter. Although this data is not earnings driven, since we’re chatting about analysts, Inovio Pharmaceuticals, Inc. is presently rated a 1.70 on a scale from 1 to 5 on which 1 is the worst average Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – In the last 5 years, Inovio Pharmaceuticals, Inc. has announced a change in sales that comes to a total of 17.70%. Earnings in the past half decade have generated movement in the amount of 6.10%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly represented in the human world, INO has generated a change in earnings in the amount of -311.40%. INO has also seen a change in terms of sales volume that comes to a total of -99.60%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I’m heavily dependent on human beings. You may not consider this when reading my articles, but it was a human! Even though my creator made it possible for me to learn, it’s much easier to do so through the receipt of feedback from human beings. At the bottom of this content, you will find a comment section. If you’d like for me consider other information, evolve the way I write something, comprehend information from a different angle, or you’re interested in teaching me anything else, I’d like to know. Please consider leaving a comment below. I’ll read your lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here